Back to PFE Stock Lookup

Pfizer (PFE) – Press Releases

May 5, 2016 07:01 AM WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
May 3, 2016 06:45 AM PFIZER REPORTS FIRST-QUARTER 2016 RESULTS
Apr 28, 2016 12:00 PM Pfizer Hosts Annual Meeting of Shareholders
Apr 26, 2016 08:30 AM Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled
Apr 22, 2016 06:30 PM CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet
Apr 21, 2016 02:00 PM Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders
Apr 19, 2016 08:00 AM Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)
Apr 15, 2016 06:00 AM On the Latest BizWireTV Cars Get Night Vision and Healthy Eating Made More Accessible
Apr 7, 2016 10:47 AM A.M. Best Affirms Ratings of Blue Whale Re Ltd.
Apr 7, 2016 08:30 AM Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care
Apr 6, 2016 11:00 AM Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®
Apr 6, 2016 06:45 AM Pfizer Announces Termination of Proposed Combination with Allergan
Apr 6, 2016 06:45 AM Allergan Reiterates Strong Standalone Growth Profile and Strategy Following Termination of Pfizer Transaction
Apr 5, 2016 05:34 PM FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications
Apr 5, 2016 09:30 AM Remedy Pharmaceuticals Appoints Dr. Thomas R. Zimmerman Jr. as Vice President, Medical Affairs
Apr 5, 2016 08:00 AM Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
Apr 5, 2016 08:00 AM Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
Apr 5, 2016 07:00 AM Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Apr 4, 2016 07:05 PM Pfizer and Allergan Issue Statement
Apr 4, 2016 09:00 AM Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
Apr 1, 2016 08:00 AM Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
Mar 31, 2016 04:29 PM Pfizer Inc. (NYSE: PFE) today issued the following statement:
Mar 30, 2016 12:41 PM Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination
Mar 30, 2016 07:45 AM Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session
Mar 23, 2016 04:15 PM Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ® (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis
Mar 22, 2016 10:00 AM Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
Mar 22, 2016 08:30 AM Pfizer Joins The Human Vaccines Project To Help Decode The Immune System
Mar 18, 2016 11:00 AM Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials
Mar 16, 2016 08:00 AM Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO
Mar 15, 2016 01:53 PM Pfizer Celebrates a Year of Achievements in 2015 Annual Review
Mar 11, 2016 01:10 PM XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Mar 9, 2016 08:00 AM New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain
Mar 9, 2016 06:45 AM Pfizer Commences $5 Billion Accelerated Share Repurchase
Mar 8, 2016 05:00 PM Pfizer Announces Publication of Study Results of BeneFIX® Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis for Hemophilia B
Mar 3, 2016 07:15 AM Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Mar 3, 2016 07:00 AM Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Mar 1, 2016 11:30 AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Feb 29, 2016 07:55 AM GNS Healthcare Study with Pfizer Reveals Discovery of Novel Clinical Risk Factors Driving Progression to Type 2 Diabetes and Prediabetes
Feb 24, 2016 12:12 PM ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir
Feb 24, 2016 11:15 AM Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
Feb 23, 2016 02:49 PM ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment
Feb 22, 2016 11:06 AM GSK's Global HIV Business ViiV Healthcare Completes Transactions to Acquire Bristol-Myers Squibb's R&D HIV Assets
Feb 19, 2016 04:35 PM Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer
Feb 16, 2016 06:45 AM WYETH REACHES AGREEMENT IN PRINCIPLE TO RESOLVE MEDICAID DRUG REBATE CLAIMS FOR 2001-2006 PERIOD FOR PROTONIX
Feb 9, 2016 06:57 PM Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications
Feb 8, 2016 09:30 AM Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction
Feb 2, 2016 06:45 AM PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS
Feb 1, 2016 06:55 AM Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Jan 21, 2016 09:05 AM Philogen Announces Exercise of Options Within the License Agreement With Pfizer Inc. for the Development and Potential Commercialization of Multiple Antibody Drug Conjugates (ADCs) and Targeted Techno
Jan 19, 2016 08:30 AM ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

Back to PFE Stock Lookup